Group 1 | Group 2 | |||||||
---|---|---|---|---|---|---|---|---|
Cut-off of FibroTest | Sensitivity | Specificity | Positive Predictive Value | Negative Predictive Value | Sensitivity | Specificity | Positive Predictive Value | Negative Predictive Value |
Stage F2F3F4 | Prevalence = 0.24 (40/170) | Prevalence = 0.32 (31/97) | ||||||
0.30 | 0.83 (33/40) | 0.78 (101/130) | 0.53 (33/62) | 0.94 (101/108) | 0.71 (22/31) | 0.74 (49/66) | 0.56 (22/39) | 0.84 (49/58) |
0.70 | 0.18 (7/40) | 0.98 (128/130) | 0.78 (7/9) | 0.80 (128/161) | 0.13 (4/31) | 0.98 (65/66) | 0.80 (4/5) | 0.71 (65/92) |
Stage F3F4 | Prevalence = 0.12 (20/170) | Prevalence = 0.16 (16/97) | ||||||
0.30 | 0.95 (19/20) | 0.71 (107/150) | 0.31 (19/62) | 0.99 (107/108) | 0.88 (14/16) | 0.69 (56/81) | 0.36 (14/39) | 0.97 (56/58) |
0.70 | 0.25 (5/20) | 0.97 (146/150) | 0.56 (5/9) | 0.91 (146/161) | 0.25 (4/16) | 0.99 (80/81) | 0.80 (4/5) | 0.87 (80/92) |
% of patients with FT between 0.30–0.70 | 0.32 (54/170) | 0.35 (34/97) |